Unrestricted funding gives BIDMC the flexibility to move forward by making immediate investments in a wide range of areas such as innovative research programs, the most advanced equipment and technology, and the recruitment of the world’s top clinicians and investigators.
BIDMC is home to many world-renowned cancer researchers, several of who have received international recognition for their innovative work.
Jill and Hung Cheng recently established the Cheng and Tsui Center for
Integrative Care, which will transform BIDMC’s primary care practice into one
that combines the best healing methods from around the world with conventional
medicine.
Two BIDMC researchers—Martin Sanda, M.D., and Steven Balk, M.D., Ph.D.—each received $1 million Challenge Awards from the Prostate Cancer Foundation (PCF).
Martin Pollak, M.D., chief of the Division of Nephrology at BIDMC, recently led
a groundbreaking study that sheds light on why so many more African Americans
develop kidney disease than people of European descent.
Two BIDMC researchers—Martin Sanda, M.D., and Steven Balk, M.D., Ph.D.—each received $1 million Challenge Awards from the Prostate Cancer Foundation (PCF). With this support, they will lead two cross-disciplinary teams of investigators who are pursuing new treatments for patients with advanced prostate cancer. The PCF Challenge Awards support a total of 10 scientific projects nationwide—and BIDMC was the only institution to receive funding for two projects.
BIDMC is home to many world-renowned cancer researchers, several of who have received international recognition for their innovative work. For instance, Pier Paolo Pandolfi, M.D., Ph.D., director of research in our Cancer Center, and Lewis Cantley, Ph.D., director of BIDMC’s Cancer Center and chief of the Division of Signal Transduction, each received the prestigious Pezcoller Foundation-AACR (American Association for Cancer Research) International Award for Cancer Research for their groundbreaking work, making Beth Israel Deaconess the only institution in the world with two recipients on its faculty. In addition, Stand Up To Cancer named Dr. Cantley the leader of a “Dream Team” of physician-researchers that received a three-year grant to study the role of PI3K mutations in women’s cancers.
Unrestricted funding gives BIDMC the flexibility to move forward by making immediate investments in a wide range of areas such as innovative research programs, the most advanced equipment and technology, and the recruitment of the world’s top clinicians and investigators. Over the past two years, our generous donors have helped raise $13.9 million in unrestricted funds, which have supported the Medical Center’s highest priorities—and, in the process, are ensuring that patients continue to receive the compassionate, advanced care they expect, and deserve, from a major medical center like BIDMC.
Martin Pollak, M.D., chief of the Division of Nephrology at BIDMC, recently led a groundbreaking study that sheds light on why so many more African Americans develop kidney disease than people of European descent. Dr. Pollak and his research team found that two common genetic variations in a gene called APOL1 are responsible for African Americans’ greatly increased susceptibility to kidney disease—variations that likely became common because they protect against African sleeping sickness. For the first time ever, scientists can use these findings to develop more effective personalized drug treatments based on the genetics of inherited kidney disease.
Jill and Hung Cheng recently established the Cheng and Tsui Center for Integrative Care, which will transform BIDMC’s primary care practice into one that combines the best healing methods from around the world with conventional medicine. Their hope is for health care providers from all disciplines to collaborate and offer the best from the East and the West in health care to help heal their patients while supporting healthy lifestyles and promoting the practice of preventative care.
- Kris Laping
Senior Vice President
Office of Development
Saying ‘thank you’ is one of the most meaningful ways to show appreciation. At Beth Israel Deaconess Medical Center (BIDMC), we have many reasons to say ‘thank you.’ This past year, the Medical Center made promising advances in research, enhanced our compassionate care, and welcomed new world-renowned leaders. These important accomplishments were made possible in large part thanks to you. So, to our donors, we extend a heartfelt ‘thank you’ for your generous support of BIDMC.
We have carefully reviewed all gifts made to Beth Israel Deaconess Medical Center and Grateful Nation to ensure that each gift is properly recognized. A description of the criteria for inclusion precedes each section of the donor lists that follow.
Occasionally, despite our best efforts, errors occur. If we have made a mistake, we sincerely apologize. Please alert us to such errors by contacting the Office of Development at (617) 667-7330 or donorrelations@bidmc.harvard.edu.
Please note that we make every effort to follow donors’ preferences when compiling the donor rolls. If you would prefer to have your name listed differently in the future, please let us know.